Anthracyclines are a critical component of adjuvant chemotherapy regimens for high-risk early breast cancer - The Henderson article reviewed [Can we abandon anthracyclines for early breast cancer patients?] Journal Article

  

Authors:	Morris, P. G.; Hudis, C. A.; Dang, C. T.
Article Title:	Anthracyclines are a critical component of adjuvant chemotherapy regimens for high-risk early breast cancer - The Henderson article reviewed [Can we abandon anthracyclines for early breast cancer patients?]
Keywords:	dna binding protein; dna-binding proteins; mortality; dose response; antineoplastic agents; note; antineoplastic agent; metabolism; antineoplastic combined chemotherapy protocols; epidermal growth factor receptor 2; tumor markers, biological; risk factors; dose-response relationship, drug; breast neoplasms; tumor antigen; tumor marker; risk factor; antigens, neoplasm; breast tumor; receptor, erbb-2; anthracycline; dna topoisomerase (atp hydrolysing); anthracyclines; dna topoisomerases, type ii; dna topoisomerase ii alpha
Journal Title:	Oncology (Norwalk)
Volume:	25
Issue:	2
ISSN:	0890-9091
Publisher:	C M P Medica LLC * The Oncology Group
Date Published:	2011-02-01
Start Page:	134
End Page:	135, 138, 140
Language:	English
PROVIDER:	scopus
PUBMED:	21456384
DOI/URL:	http://www.scopus.com/inward/record.url?eid=2-s2.0-79954432114&partnerID=40&md5=490395ed84bc7de0baa1b41e72df5fba
Notes:	--- - "Export Date: 23 June 2011" - "Source: Scopus"

https://synapse.mskcc.org/synapse/works/has_related_data_chk/5849